Originally published by our sister publication Clinical Oncology News
By Clinical Oncology News Staff
The FDA has approved datopotamab deruxtecan-dlnk (Datroway, Daiichi Sankyo), a Trop-2−directed antibody and topoisomerase inhibitor conjugate, for adult patients with unresectable or metastatic, hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative (IHC 0, IHC1+ or IHC2+/ISH−) breast cancer who have received prior endocrine-based therapy and